-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, the results of the drug registration progress inquiry of China's National Food and Drug Administration (NMPA) showed that Novo Nordisk (Novo Nordisk) submitted a new drug listing application for smegaglutide injection, the status has been updated to "pending approval.
" This means that the registration of this long-acting GLP-1 analog, which only needs to be injected once a week, has gone further in China.
If approved successfully, it will bring new treatment options to Chinese patients with type 2 diabetes.
Type 2 diabetes is a serious disease.
This disease is often caused by the inability of the body to produce enough insulin or the inability to properly use the insulin synthesized by the body.
Semaglutide (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog, which can act as a GLP-1 receptor agonist and can bring cardiovascular and metabolic gains to patients.
According to the results of the SUSTAIN China study recently released by Novo Nordisk, this study is a registered clinical trial of smeglutide in China.
The results showed that after 30 weeks, smeglutide significantly reduced HbA1c by 1.
The review and approval status of smegaglutide in China's listing application has entered pending approval, which means that this product is one step closer to being approved in China.
Pharmaceutical Mission Hills
Pharmaceutical Mission Hills
Observe the waves of Chinese medicine and compose the chapter of global new medicine.
1332 original content
the public
